Retatrutide vial 10mg

Retatrutide — Triple-Agonist Research Peptide

Retatrutide is an investigational peptide attracting significant research interest due to its unique triple-receptor mechanism, targeting GLP-1, GIP, and glucagon receptors. This combination is being studied for its potential effects on appetite regulation, energy balance, glucose metabolism, and overall metabolic function.

Research into retatrutide has demonstrated several promising areas of interest, including:

• Significant reductions in body weight observed in clinical studies

• Reduced waist circumference and overall body-fat-related measurements

• Improvements in blood glucose control and insulin-related metabolic markers

• Improvements in triglycerides, cholesterol markers, and blood pressure

• Potential effects on appetite, food intake, and energy expenditure through its triple-agonist mechanism

• Improvements in certain obesity-related complications, including obstructive sleep apnea and knee osteoarthritis symptoms, in clinical trials

• Improvements in physical function and quality-of-life measures reported in Phase 3 research

In the Phase 3 TRIUMPH-1 study, participants receiving the highest studied dose experienced an average body-weight reduction of 28.3% at 80 weeks. Improvements were also observed across several cardiometabolic measures, including waist circumference, triglycerides, blood pressure, glycemic markers, and inflammatory markers.

Retatrutide remains an investigational compound and has not been approved for general medical use. Research into its safety, effectiveness, and potential applications is ongoing.

FOR RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION.